GCP
CRNX icon

GSA Capital Partners’s Crinetics Pharmaceuticals CRNX Stock Holding History

GSA Capital Partners’s Portfolio CRNX Stock Details CRNX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-9,083
Closed -$323K – 1669
2023
Q4 		$323K Sell
9,083
-1,942
-18% -$59.6K 0.03% 1074
2023
Q3 		$328K Sell
11,025
-24,163
-69% -$498K 0.03% 1023
2023
Q2 		$634K Buy
35,188
+5,733
+19% +$114K 0.06% 586
2023
Q1 		$473K Buy
+29,455
New +$545K 0.05% 748
2022
Q2 		– Sell
-14,897
Closed -$327K – 1450
2022
Q1 		$327K Buy
14,897
+2,562
+21% +$51.9K 0.04% 832
2021
Q4 		$350K Sell
12,335
-4,145
-25% -$102K 0.04% 834
2021
Q3 		$347K Buy
+16,480
New +$345K 0.04% 917

Other funds holding CRNX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $4.89B AUM 251.12% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

GSA Capital Partners's CRNX Position: Q1 2024 in Review

GSA Capital Partners sold out of Crinetics Pharmaceuticals (CRNX) in Q1 2024, closing a stake of 9,083 shares — an estimated $323K sold.

GSA Capital Partners first reported a position in CRNX in Q3 2021 and held it in 7 quarters. The position peaked at $634K in Q2 2023. 203 funds tracked by Wall St. Rank hold CRNX as of Q1 2024.

  • GSA Capital Partners reported no remaining Crinetics Pharmaceuticals position as of Q1 2024 after selling out during the quarter.
  • GSA Capital Partners sold 9,083 Crinetics Pharmaceuticals shares in Q1 2024, an estimated $323K.
  • GSA Capital Partners first reported a position in Crinetics Pharmaceuticals in Q3 2021 and held it in 7 quarters.
  • GSA Capital Partners's Crinetics Pharmaceuticals position peaked at $634K in Q2 2023.
  • 203 funds tracked by Wall St. Rank held Crinetics Pharmaceuticals as of Q1 2024.

Based on GSA Capital Partners's 13F filing for Q1 2024, filed 3 May 2024.